Warner Chilcott’s Launch Of Atelvia Hits Headwinds
It has been a difficult year for Warner Chilcott PLC. But not an unexpected one.
You may also be interested in...
Actavis’ purchase of Warner Chilcott will lower the former’s overall tax rate significantly, expand its specialty pharma business to 25% of total revenues, and provide global critical mass – all necessary responses to a future that includes fewer opportunities for small molecule generics and greater pricing pressures.
As second quarter earnings announcement shift into high gear, companies announce changes to manufacturing, progress on their drug launch efforts and their intentions to ramp up business development efforts.
With Bayer reportedly preparing to strike a multi-billion-dollar deal, investors are reacting by driving up the price of two different potential targets.